SOMERSET, N.J., February 20, 2025--(BUSINESS WIRE)--Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...